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1 
Abstract 
 
Introduction: The proven pathological alterations in the kynurenine pathway of tryptophan 
metabolism either in preclinical models of neurological and psychiatric disorders or in human 
samples themselves elicited numerous attempts to restore the altered balance via 
pharmaceutical manipulation of the pathway. 
Areas covered: The aim of the authors was to conduct a review of relevant scientific data on 
enzyme inhibitors of the kynurenine pathway, with a special attention to pipeline drug 
development strategies based on relevant patent literature, covering the period of 2012-2015. 
Considering the magnitude of the topic, only the most prominent examples of lead 
compounds and substances necessary to enlight structure activity relationships were reported. 
Expert opinion: Although the clinical and preclinical data are reassuring, there is a lack of 
applicable drugs in daily clinical practice. However, the recent determination of enzyme 
structures considerably promoted the development of potent inhibitors, most of them have 
been designed as a structural analog of the natural enzyme substrate. Especially, the inhibition 
of indolamine 2,3-dioxygenase in central nervous system tumors, the inhibition of kynurenine 
aminotransferase in cognitive dysfunction and the inhibition of kynurenine 3-monooxygenase 
in neurodegenerative disorders, such as Huntington’s disease, alike provide a great promise. 
 
Keywords:inhibitors, kynurenine pathway, neurotherapeutics, tryptophan metabolism 
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Article highlights 
• The kynurenine pathway of tryptophan metabolism serves as an interesting drug target 
in certain neurological and psychiatric conditions. 
• Amongst therapeutic options, the development of enzyme inhibitors would be one of 
the leading optionsforin pharmaceutical manipulation of pathological alterations. 
• In light of preclinical data, especially the inhibitors of indolamine 2,3-dioxygenase, 
kynurenine aminotransferase and kynurenine 3-monooxygenase could exert beneficial 
effects in future clinical studies. 
• Probably the most extensively studied field is that of the kynurenine 3-
monooxygenase inhibitors, highlighting the lead compounds of trans-2-substituted-
cyclopropane-1-carboxylic acids, phenylthiazole, phenylthiadiazole and pyrimidine 
benzenesulfonamides, and aryl pyrimidines. 
• The reassuring preclinical data warrant future well-designed clinical studies to 
beenable to determine which the identification of compounds that may provide relief 
in some devastating neurological and psychiatric illnesses. 
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Abbreviations 
3-HAO – 3-hydroxyanthranilate 3,4-dioxygenase 
3-OH-ANA – 3-hydroxyanthranilic acid 
3-OH-L-KYN – 3-hydroxy-L-kynurenine  
4-chloro-L-KYN – 4-Cl-L-KYN 
AD – Alzheimer’s disease 
AMPAR – α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors 
BBB – blood-brain barrier 
CNS – central nervous system 
FAD – flavin adenine dinucleotide 
GPR35 – G protein-coupled receptor 35 
HD – Huntington’s disease 
IC50 – half maximal inhibitory concentration 
IDO – indolamine 2,3-dioxygenase 
IFN – interferon 
KAT – kynurenine aminotransferase 
KMO – kynurenine 3-monooxygenase 
KYN – kynurenine 
KYNA – kynurenic acid 
mitAAT – mitochondrial aspartate aminotransferase 
NAD
+
 – nicotinamide adenine dinucleotide 
NADP
+ 
– nicotinamide adenine dinucleotide phosphate 
NMDAR – N-methyl-D-aspartate receptor 
PLP – pyridoxal-5‘-phosphate 
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4 
QUIN – quinolinic acid 
SAR – structure activity relationship 
TDO – tryptophan 2,3-dioxygenase 
TRP – tryptophan 
Page 4 of 64
URL: http://mc.manuscriptcentral.com/eotp  Email: Julia.Galway-Witham@informa.com
Expert Opinion On Therapeutic Patents
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
5 
 
1. The kynurenine pathway of tryptophan metabolism 
The kynurenine (KYN) pathway is the main route of tryptophan (TRP) metabolism (Fig. 1.; 
[1]), more than 95% of TRP is metabolized through kynurenines[2]. This pathway consists of 
several neuroactive metabolites and ensures provides the major source of nicotinate [3] for the 
production of nicotinamide adenine dinucleotide (NAD
+
)and nicotinamide adenine 
dinucleotide phosphate (NADP
+
) coenzymes. The neuroactive kynurenines include kynurenic 
acid (KYNA), 3-hydroxy-L-KYN (3-OH-L-KYN), and quinolinic acid (QUIN), and 
alterationsin their levels have proven pathogenic roles in several neurological and psychiatric 
conditions [4]. KYNA is a wide-spectrum endogenous antagonist of ionotropic excitatory 
amino acid receptors[5]. In micromolar concentrations, in addition to exerting a weak 
antagonistic effect on α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors 
(AMPARs) and kainate receptors [6]it displays competitive antagonism at the strychnine-
insensitive glycine-binding site of the N-methyl-D-aspartate receptor (NMDAR; [7]). In 
addition to its inhibitory profile, in nanomolar concentrations it is capable of facilitating 
AMPAR responses, raising the possibility of partial agonism[8]. Previously it was believed 
that Ddespite the above-described broad action at glutamatergic receptors, the main 
mechanism of action of KYNA on glutamatergic neurotransmission at physiologically 
relevant nanomolar concentrations would be mediated via the non-competitive blockade of 
α7-nicotinic acetylcholine receptors at glutamatergic terminals[9], the activation of which is 
involved in the regulation of glutamate release[10]. However, the results of the study 
presented by Hilmas et al. [9]could not be repeated by experiments of four different, 
independent laboratories, indicating that KYNA may not influence glutamate release via the 
blockade of α7-nicotinic acetylcholine receptors[11-14]. These contradictory findings may be 
attributable to a non-specific effect produced by dimethyl sulfoxide applied as a solvent for 
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6 
KYNA.Nevertheless other possible reasons such as regional or species differences, or the age 
of the preparation could not be accounted for the observed contradictory results [14]. 
Although it has been reported as well that KYNA can elicit inositol trisphosphate production 
and Ca
2+
 mobilization through the activation of G protein-coupled receptor GPR35 (GPR35) 
[15], the role of this phenomenon is questionable as regards the central nervous system (CNS) 
due to the limited expression of GPR35 in the brain. In addition to acting on cell surface 
receptors, it is suggested that KYNA can also exert potent free radical scavenging and 
antioxidant effects[16]. With regard to 3-OH-L-KYN, its deleterious effects are proposed to 
be mediated by free radicals and not by glutamate receptors[17]. Some of the toxic actions of 
3-OH-L-KYN may be due attributable to its metabolite, 3-hydroxyanthranilic acid (3-OH-
ANA), which readily undergoes auto-oxidation with the production of O2
.-
[18], resulting in 
neurotoxic properties [19]. QUIN is a weak, but specific competitive agonist with low 
receptor affinity at the NMDAR subgroup containing GLUN2A and GLUN2B subunits [20], 
the latter having a special role in mediating glutamate-induced excitotoxicity [21]. In addition 
to the direct activation of NMDARs, QUIN can evoke the release and inhibit the uptake of 
glutamate as well [22]. Furthermore, the production of reactive oxygen intermediates and the 
induction of lipid peroxidation also contribute to the neurotoxic effects of QUIN [23]. Several 
neurological conditions can be characterized by the absolute or relative decrease in KYNA 
concentrations and the elevation of 3-OH-L-KYN and QUIN [4,24-26]. However, the 
excessive elevation of KYNA can also have detrimental effects, such as the impairment of 
cognitive functioning in schizophrenia [27,28]and Alzheimer’s disease (AD) [29-31]. In light 
of the above-mentioned data, there are 3 main ways of achieving neuroprotection targeting the 
kynurenine pathway: the prodrug, the KYNA analog and the metabolic shift concepts [4]. 
With regard to the metabolic shift concept, many enzyme inhibitors have been developed with 
the aim of restoratversing pathological alterations at the level of neuroactive 
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7 
kynurenines.Although the question may arise whether the inhibition of TRP metabolism 
results in pathological decrease of de novo NAD
+
 biosynthesis [32], the existence of the 
salvage pathway most probably provides a sufficient compensation through an appropriate 
exogenous intake of niacin, especially in light of the fact that niacin deficiency could result in 
pellagra, a disease linked to chronic systemic depletion of NAD
+
. 
 
2. Structure and function of certain enzymes of the kynurenine pathway 
and their inhibitors as neurotherapeutics 
2.1 Indolamine 2,3-dioxygenase 1 and 2, tryptophan 2,3-dioxygenase 
The conversion of L-TRP by indolamine 2,3-dioxygenase (IDO, also known as IDO1, EC: 
1.13.11.52) and tryptophan 2,3-dioxygenase (TDO, also known as TDO2, EC: 1.13.11.11) 
enzymes to N-formyl-KYN is the rate-limiting step of the synthesis of L-KYN and the KYN 
pathway itself. Although IDO1 shares very limited homology with TDO at amino acid level, 
both enzymes are b-type heme-dependent cytosolic dioxygenases and their mechanism of 
action includes the incorporation of two atoms of mol cular oxygen into the indole ring of 
their substrate [33]. Enzyme-structure studies, yielding three dimensional models as well, 
demonstrated that IDO is a monomeric, two-domain enzyme comprising one molecule of 
heme b [34], whereas TDO is a tetrameric protein comprising four molecules of heme 
b[35,36]. A third, more recently identified tryptophan catabolic enzyme is IDO2 (also known 
as INDOL1, EC: 1.13.11.-), which is structurally similar to IDO and is encoded adjacently 
[37,38]. It is, however, unclear if IDO2 is functionally active in humans [39,40], and its 
relevance in conditions affecting the human neural system has not yet been demonstrated. 
IDO is widely expressed in the body including the CNS; however, it is more abundantly 
expressed in immune cells (especially antigen-presenting cells such as macrophages and 
dendritic cells) and the placenta. In contrast, TDO is preferentially expressed in the liver. 
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8 
Unlike TDO, IDO is readily inducible by various inflammatory stimuli, including interferon-α 
(IFNα), IFNβ and IFNγ, interleukin-1 and -2, tumor necrosis factor, cytotoxic T lymphocyte 
antigen 4, transforming growth factor β, and lipopolysaccharide [41]. The activation of the 
KYN pathway has in turn immunosuppressive properties, mediated in part via TRP depletion, 
and the elevated levels of KYN, 3-OH-KYN, 3-OH-ANA, and QUIN, which lead to the 
suppressed proliferation and increased apoptosis of activated T helper 1 lymphocytes, as well 
as the increase in the number of regulatory T cells [4]. The immunosuppressive effect of 
placental IDO activation and downstream kynurenines is thought to be responsible for 
maternofetal immune tolerance, and its fingerprint in terms of elevated KYN/TRP ratio has 
recently been evidenced from human umbilical cord vein serum samples [42]. Increased IDO 
activation has been linked to various neurological and psychiatric disorders where 
neuroinflammation is implicated at some point of the pathogenesis, including Parkinson’s 
disease, Huntington’s disease (HD), AD, multiple sclerosis, amyotrophic lateral sclerosis, 
cerebral ischemia, CNS infections and major depression (widely reviewed in [4]). On the 
other hand, elevated TDO expression, increased KYNA levels, and elevated kynurenine 3-
monooxygenase (KMO) activity have been observed in regions preferentially involved in 
schizophrenic patients, with increased KYNA and decreased QUIN levels measured in the 
cerebrospinal fluid, alterations suggested to essentially contribute to the cognitive deficits 
observed in the disease [4,43,44]. The development of cognitive dysfunction via increased 
KYNA levels maybe attributableto its excessive anti-glutamatergic effect, as detailed later. 
The high expression of both IDO and TDO has been linked to a variety of tumors (including 
that formed in the CNS;[45,46]), and they are thought to be in part responsible for mediating 
tumor camouflage via providing an immunosuppressive milieu. The role of IDO2 in tumor 
survival has also recently gained an intensive research interest. By far the most extensively 
examined inhibitor of IDO is the substrate analogue 1-methyl-TRP, more specifically theits D 
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9 
stereoisomer 1 (1-methyl-D-TRP,also known as indoximod, NLG8189). Interestingly, while 
1-methyl-L-TRP is far more effective in inhibiting IDO in vitro in cell-free and some cell 
culture assays (Ki = 19 µM), the D stereoisomer is reported to be highly superior among in 
vivo conditions,:it shows anti-tumor effect [47], and it has already been involved in clinical 
trials as standalone or add-on therapy to boost anti-cancer immunity [45].In particular, 1 is 
used together with temozolomide in a trial enrolling patients with primary brain malignancies 
(NCT02052648). In addition to the lead molecule, a hydroxamidine derivative 2 
(INCB024360; (4ε)-4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-
amine) with most advanced pharmacological profile (IC50 = 7-15 nM in cell culture assays, 72 
nM in cell-free assay; [48]), and 3 (NGL919; (1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-
yl)ethanol) with similar pharmacological properties (IC50 = 7 nM[49]) and with an in vivo 
effect on murine glioblastoma comparable to that achieved with 1[50]have also been 
introduced as candidate biological therapies in clinical trials of malignancies, though not yet 
of CNS tumors. A comprehensive compilation of natural and synthetic IDO inhibitors with 
different pharmacological properties is provided in a prior publication [4]. 
The lead TDO inhibitor molecule is 4 (680C91; 6-Fluoro-3-[(1ε)-2-(3-pyridinyl)ethenyl]-1H-
indole; Ki = 51 nM[51]), whereas and the development of orally available indole derivatives 
have also been reported [52], including compound 5 (LM10; 6-fluoro-3-[(E)-2-(1H-tetrazol-5-
yl)vinyl]-1H-indole) with the most promising profile (Ki = 5.5 µM). LM10 appears to be 
effective in preclinical use [53]. 
The role of IDO/TDO inhibition in neurodegenerative disorders where alterations have been 
published is not as deeply explored as in case of malignancy. Compound 6 (coptisine 
chloride; 6,7-dihydro-bis(1,3)benzodioxolo[5,6-a:4',5'-g]quinolizinium chloride; IC50 = 6.3 
µM), a component of a traditional Chinese medication Oren-gedoku-to hasve been reported to 
be beneficial in a murine model of AD [54]. On the other hand, genetic inhibition of TDO has 
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10 
been shown to ameliorate the phenotype of a transgenic Drosophila model of HD [55]and 
similarly, genetic inhibition of IDO was protective against QUIN-induced striatal 
neurotoxicity in mice [56]. Furthermore, inhibition of IDO with 1 abrogated systemic 
inflammation-induced depressive behavior in mice [57,58]. The genetic ablation or 1-induced 
inhibition of IDO in mice, however, did not influence infarct size and overall outcome in an 
acute stroke model of mice [59]. Further research is needed to establish the therapeutic 
potential of IDO/TDO inhibition in disorders associated with neurodegeneration and/or 
neuronal dysfunction. The structure of the above-mentioned inhibitors of IDO and TDO are 
demonstrated in Fig. 2. 
 
2.2 Kynurenine aminotransferases 
There are four subtypes of kynurenine aminotransferases (KATs, EC: 2.6.1.x; reviewed in 
[60]: KAT-I-II [61], KAT-III [62]and mitochondrial aspartate aminotransferase (mitAAT, also 
called KAT-IV) [63]). KATs belong to the α-family of pyridoxal-5‘-phosphate (PLP)-
dependent enzymes and they are responsible for the irreversible transamination of L-KYN 
resulting in the production of KYNA. The KATs are abundantly expressed in astrocytes [64], 
and the expression of KAT-II is confined entirely to these cell types [65],with only weak 
granular staining visible in neurons [66]. With regard to the expression level of different KAT 
subtypes, a difference between species can be observed: KAT-II has been demonstrated to be 
the main KYNA-producing enzyme in the rat and human brains, while in the mouse brain 
mitAAT has the highest activity [63]. However, following the discovery that the neglected 
role of KAT-I under physiological conditions would can be attributed to methodological 
reasons, it can be assumed that KAT-I may also contribute to the in vivo formation of KYNA 
[60]. In addition to the assessment of the pathobiochemistry of the KYN pathway, in light of 
the fact that genetic elimination of KAT-II can improve cognitive functioning [31], the 
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11 
development of KAT inhibitors may have therapeutic potential, as well [4,67]. The rationale 
ofa potential therapeutic improvement of cognitive functionsin conditions characterized by 
elevated brain KYNA levels, such as schizophrenia or AD, would be that normalizing KYNA 
levels would result in the decrease of pathological inhibition of glutamatergic 
neurotransmission and thereby long term potentiation, phenomena necessary for memory 
formation.Studies on the structure function relationship of human KAT-II revealed that within 
each of the 2 active sites in the functional dimer the PLP-binding pocket harbors the cofactor 
molecule in Schiff-base linkage to the ε-amino group of the catalytic residues Lys-263 of the 
corresponding subunit [68]. These observations in three dimensional models are essential for 
drug design targeting the active site of the enzyme. With regard to KAT-II inhibition, non-
selective (e.g. 7; dichlorovinylcysteine; IC50 = 30-100 µM [69]) and selective inhibitors also 
exist (Fig. 3.). The spectrum of selective KAT-II inhibitors consists of less potent natural (e.g. 
8; quisqualic acid; ((2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid); IC50 
= 200-520 µM [69,70]), endogenous natural (e.g. 9; S-adenosylhomocysteine; IC50 = 30-100 
µM [71]), and synthetic (e.g. 10; 4-carboxy-3-hydroxyphenylglycine; 49% inhibition at 200 
µM [70]), as well as more potent endogenous natural (e.g. 11; L-cysteinsulphinic acid; IC50 = 
2 µM [72]) and synthetic (e.g. 12; (S)-(4)-(ethylsulfonyl)benzoylalanine; IC50 = 6 µM [73]) 
substances. Compounds 11 and 12 were demonstrated to be not only pure competitive 
inhibitors, but also to be substrate analogs[74]. Accordingly, whichthe latter one could 
significantly improve the performance in the Morris water maze cognitive test following 
intracerebroventricular administration [75]. FurthermoreHowever, in addition to the 
development of second-generation drugs with better inhibitory potency (e.g. 13; BFF-122; 
(S)-10-(4-aminopiperazin-1-yl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxylic acid; 43% inhibition at 1 µM [76]), there are 2 other problems 
emerging: the penetrationacrossthrough the blood-brain barrier (BBB) and the observation 
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12 
that sequence variants in human and rat KAT-II would cause significant cross-species enzyme 
potency shifts for 12[77,78], i.e. this substance was disappointingly almost inactive on 
humans. Compound 14 (BFF-816; (5Z)-5-[(3-{11-oxo-1-azatricyclo[6.3.1.0{4,12}]dodeca-
4(12),5,7-trien-7-yl}phenyl)methylidene]-1,3-thiazolidine-2,4-dione) is capable of reducing 
extracellular levels of KYNA in the striatum, hippocampus and prefrontal cortex following 
oral administration at the dose of 30 mg/kg in rats and could improve cognitive performance 
in the Morris water maze test [79]. Compound 15 (PF-04859989; (3S)-3-amino-1-hydroxy-
3,4-dihydroquinolin-2(1H)-one) is selective inhibitor of human KAT-II (IC50 = 23 nM) over 
human KAT-I, KAT-III and KAT-IV (IC50 values of 22, 11, and > 50 µM, respectively [80]). 
Furthermore, the potency shift between human and rat KAT-II (IC50 = 263 nM) is considered 
to be modest, which allows the application of this compound in preclinical rodent models. 
Similarly to 13, 15 covalently binds to the enzyme cofactor PLP in the catalytic pocket, 
creating an irreversible adduct. Additionally, the functional triad of the 3-aminohydroxamic 
acid moiety of 15 consists of the H-bond formations of carbonyl oxygen with the side chain 
of Asn-202 and that of the other oxygen atom in the hydroxamic acid functionality with Arg-
399. The structure-activity relationship (SAR) studies with regard to assessing the role of 3-
aminohydroxamic acid moiety in inhibitory activity revealed that the (S)-enantiomer is 
approximately 10-fold more potent compared to the (R)-enantiomer, and the methylation of 
hydroxamic acid group or the introduction of a methyl group at the C-3 position likewise 
resulted in a complete loss of activity. Furthermore, the fused phenyl moiety of the molecule 
contributes to the van der Waals interactions with the hydrophobic pocket of KAT-II formed 
by Leu-40, Tyr-74 and Leu-293. Preliminary SAR data suggest that substitutions at C-6 and 
C-7 positions would be used for further optimization of properties. The administration of 15 
successfully ameliorated ketamine-induced cognitive dysfunction in rats [81]. 
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13 
2.3 Kynurenine 3-monooxygenase 
3-OH-L-KYN is formed by the action of KMO (EC: 1.14.13.9 [82]). KMO is a flavin adenine 
dinucleotide (FAD)-containing enzyme localized in the outer mitochondrial membrane [83]. 
The QUIN-producing branch of the kynurenine pathway, including KMO, is mainly localized 
within microglia and macrophages [84], which associate the neurodegenerative effects of 
neurotoxic metabolites with neuroinflammation. Although the expression level of KMO is 
relatively low in the brain and higher as compared with that in the liver and kidney [85-87], 
the transport of 3-OH-L-KYN through the BBB [88]enables the exertion of its neurotoxic 
effects in the CNS following a peripheral activation. After L-KYN binding, NADPH reduces 
FAD before oxygen binding and the formation of L-KYN-FAD-hydroperoxide intermediate 
[89]. The next step is the oxidation of L-KYN,yielding 3-OH-L-KYN and water. The 
demonstration of the three dimensional enzyme structure [90]would further facilitate the 
design of KMO inhibitors.with the aim of decreasing the concentration of toxic KYN 
pathway metabolites or shifting the pathway toward KYNA production would be one of the 
leading therapeutic strategiesThe rationale in the development of these inhibitors would be the 
restoration of the physiological balance in the metabolite levels, i.e. decreasing the production 
of neurotoxic compounds (such as 3-OH-L-KYN and QUIN) and shifting the pathway into 
the production of the anti-excitotoxicKYNA, metabolites present in many neurodegenerative 
diseases in a relative excess and deficit, respectively[83]. Indeed, as the majority of 3-OH-L-
KYN is produced in the periphery, the penetration of KMO inhibitors through the BBB is not 
obligatory. With regard to KMO inhibition, the early attempts resulted in the synthesis of 
unon-selective KMO inhibitors with low potency (e.g. 16; nicotinylalanine; IC50 = 900 µM 
[91]) with inhibitory effect on kynureninase as well. However, the addition of 16 to L-KYN 
and probenecid increased the potency to protect against QUIN-mediated neurotoxicity in the 
striatum [92]and in the nigrostriatal dopaminergic system [93]. Furthermore, 16has 
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14 
anticonvulsant effects, as well [91,94,95]. The development of 4-aryl-4-oxobutanoic acids, 
such as 17 (mNBA; (m-nitrobenzoyl)alanine) resulted in higher potency (IC50 = 900 nM[96]) 
with still unon-selective activity. The lead compound 17 exerted protective effects both in 
vitro (organotypic hippocampal slice cultures) and in vivo (transient bilateral carotid 
occlusion in gerbils, permanent unilateral middle cerebral artery occlusion in rats) models of 
cerebral ischemia via the reduction of 3-OH-KYN and the increase in KYNA concentrations 
[97-99]. Furthermore, 17could alleviate kainate-induced neurotoxicity [100], and has 
anticonvulsant activity [91], as well. Compound 17 also reduced QUIN formation in immune-
activated mice [101]. Compound 18 (PNU 156561, formerly known as FCE 28833A; (R,S)-
3,4-dichlorobenzoylalanine) is also capable of exerting anti-ischemic effects, probably via 
increasing brain KYNA levels [102,103]. With regard to SAR studies in benzoylalanines, it 
can be concluded that the S-enantiomers would be are more potent (IC50 = 500 nM[104]), the 
carboxyl group is obligatory for inhibition, whereas the amine group is not [105]. Therefore 
the amine can be replaced with a methylene bridge, resulting in compound 19 (UPF 648; 
(1S,2S)-2-(3,4-dichlorobenzoyl)cyclopropanecarboxylic acid) with much higher potency (IC50 
= 40 nM) and selectivity [76,106]. In neuron-depleted striata (7 days following QUIN 
injection) 19 not only decreased 3-OH-KYN and QUIN production (by 77% and 66%, 
respectively), but moderately increased KYNA synthesis (by 27%), as well [76],and was 
proved protective in a QUIN model of HD [107]. Furthermore, 19was protective in a 
Drosophila model of HD, too as well[50]. However, the formation of hydrogen peroxide 
probably via the decay of the intermediate hydroperoxyflavin, would limit the application of 
these L-KYN-like molecules as KMO inhibitors such as, 17 or 19[90]. Sulfonamides are 
structural analogs of L-KYN, as well, containing an FAD-binding benzene ring, a five- or six-
membered aromatic ring as linker, a sulfonamide as amino-acid bioisostere and an extendable 
benzene ring [83]. The inhibitory potential is a function of the size of the linking ring, ranging 
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15 
from a minimal inhibition in case of six-membered rings (≤ 25% at 10 µM [108]) to a 
significantly more potent inhibition in case of five-membered rings, such as thiazoles[109]. 
Small substituents, such as methoxy groups, are required on both benzene rings for optimal in 
vitro binding. Accordingly, the lead compound of phenylthiazolebenzenesulfonamides is 20 
(Ro 61-8048; 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzenesulfonamide; IC50 = 
37 nM). Although drugs belonging to the sulfonamide group of KMO inhibitors have poor 
penetration through the BBB, this would not necessarily be a problem in light of the above-
mentioned fact that the majority of 3-OH-L-KYN is produced in the periphery. Accordingly, 
20increased the serum levels of KYN and KYNA and decreased the incidence of L-DOPA-
induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated cynomolgus 
monkeys, but did not affect the antiparkinsonian effect of L-DOPA [110,111]. Compound 20 
successfully improved dystonia in a genetic model of paroxysmal dyskinesias[112,113]. With 
regard to HD, 20was proved protective in yeast and Drosophila models of the disease 
[55,114]. Furthermore, similarly to 17, 20 reduced QUIN formation in immune-activated mice 
[101]and also exerted protective effects in both in vitro and in vivo models of cerebral 
ischemia via the reduction of 3-OH-KYN and the increase in KYNA concentrations [97-
99].Similarly to 16, 20proved to have anticonvulsant effects [91]. Furthermore, compound 20 
exerted substantial anti-inflammatory effects in animal models of cerebral malaria and 
trypanosomiasis [115,116]. To overcome the problem that 20 is a metabolically unstable 
compound, a potential slow-release prodrug, 21 (JM6; 2-(3,4-dimethoxybenzene-
sulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl)-methylthiazole) has been were 
developed. Although it successfully ameliorated the neurodegenerative processes in the R6/2 
transgenic mouse model of HD and a transgenic mouse model of AD overexpressing human 
amyloid precursor protein [117], later the validity of these results has been criticized in light 
of pharmacokinetic studies that 21 is neither a prodrug for 20 nor a potent KMO inhibitor 
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16 
[118]. Aryl pyrimidines would be promising candidates as KMO inhibitors, as well [119](SAR 
to be detailed later). 4-Aryl-oxobutanoates and their esters (e.g. 22;[(Z)-4-(3-fluorophenyl)-2-
hydroxy-4-oxo-but-2-enyl] acetate; IC50 = 1.6 µM [120,121]), phenylcinnamic acids (e.g. 
23;2,4-dichloro-1-[(E)-2-(2-chloro-4-methoxy-phenyl)-1-methyl-vinyl]benzene; IC50 = 0.5 
µM [115]), phenyloxadiazoles, pyrroloquinolones and 3-oxopropanenitrile molecules havealso 
been reported as well;however the available experimental data are limited [83].The structures 
of the above-mentioned inhibitors of KMO are demonstrated in Fig.4. 
 
2.4 Kynureninase 
Kynureninase (EC: 3.7.1.3), similarly to KATs, is a PLP-dependent enzyme, as well. It is 
responsible for the β,γ-hydrolytic cleavage of 3-OH-L-KYN (human and other eukaryotic 
constitutive kynureninases) and L-KYN (many prokaryotic inducible kynureninases), 
resulting in the formation of 3-OH-ANA or anthranilic acid, respectively, and L-alanine [122]. 
With regard to the structure of human recombinant kynureninase, the enzyme possesses two 
substrate binding sites: a regulatory non-catalytic site and a catalytic site [123]. The 
explanation for the possibility of two substrates despite the highly conserved active sites 
would be a slight difference in enzyme structure due to conserved point mutations, as 
demonstrated by three dimensional models[124]. In prokaryotes, the Trp69 side chain phenyl 
group γ-carbon of Thr282 form a hydrophobic patch which is unfavorable for hydrogen 
binding with the 3-hydroxyl group of 3-OH-L-KYN. Conversely, in eukaryotes, the side 
chain of His102 and the δ nitrogen of Asn333 would promote that interaction. With regard to 
the expression pattern of human kynureninase in extrahepatic cells, it is mainly expressed in 
macrophages and microglia, similarly to KMO[84]. In addition to the above-mentioned unon-
selective inhibitors, such as 16 (IC50 = 800 µM [91]) and 17 (IC50 = 100 µM [96]), some more 
potent and selective compoundsexist (Fig. 5.). With regard to SAR studies in a structural 
Page 16 of 64
URL: http://mc.manuscriptcentral.com/eotp  Email: Julia.Galway-Witham@informa.com
Expert Opinion On Therapeutic Patents
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
17 
analog of L-KYN, 24(2-amino-4-(3-hydroxyphenyl)-4-hydroxybutanoic acid; (K(i) = 40 nM 
and 100 nM for recombinant human or rat hepatic kynureninase, respectively [125,126]), 
revealed that the 2-amino group is crucial for activity, whereasile the 3-hydroxyl group 
playsed an important role in binding at the active site of kynureninase, presumably via 
hydrogen bonding. 2-Amino-S-aryl-cysteine-S,S-dioxides (the most potent is 25; 2-amino-5-
methyl-S-phenyl cysteine S,S-dioxide; IC50 = 11 µM) would present another option for the 
selective inhibition of kynureninase[127]. The 2-amino moiety appears to be essential for 
enzyme inhibition because neither of the 2-nitro-substituted compounds exerted inhibitory 
activity. With regard to the inhibition of kynureninase from Pseudomonas fluorescens, 
brominated compounds, such as 26 ((4R)-5-bromodihydro-L-kynurenine; K(i) = 55 nM) with 
slow substrate activity, as well, hasve been synthesized as well[128]. The (4S)-epimer is also a 
potent inhibitor (K(i) = 170 nM) withoutno demonstrated substrate activity. 
 
2.5 3-Hydroxyanthranilate 3,4-dioxygenase 
3-Hydroxyanthranilate 3,4-dioxygenase (3-HAO, EC: 1.13.11.6) is responsible for the 
formation of QUIN from 3-OH-ANA [129]. 3-HAO, as demonstrated by three dimensional 
models as well, is a cytosolic homodimer protein, with each subunit containing two non-heme 
ferrous irons, and it catalyzes the cleavage of the benzene ring of 3-OH-ANA [130,131]. The 
direct product of this reaction is an intermediate, α-amino-β-carboxymuconic acid ε-
semialdehyde. This unstable compound can either spontaneously arrange to QUIN or can be 
converted to picolinic acid after decarboxylation. 3-HAO is mainly localized in the liver and 
kidney, but it is also present in the CNS in low amounts [129,132]. With regard to CNS, the 
main source of 3-HAO, being the part of the QUIN-producing branch of the KYN pathway, 
are microglia [84];however, it is also expressed by astrocytes [64]. Following the early 
exploration of weak inhibitors of 3-HAO, such as 27 (m-hydroxybenzoic acid; IC50 = 480 µM 
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18 
[133]), more potent compounds have been developedlater (Fig. 6.). The systemic 
administration of 4-chloro-L-KYN (4-Cl-L-KYN), the BBB-penetrable pro-drug of 7-Cl-
KYNA, whicha molecule exertsing enhanced antagonism at the glycine/NMDA receptors, 
resulted in the prevention of QUIN- and malonate-induced neurotoxicity in the rat striatum 
[134]. 4-Cl-L-KYN is metabolized to 28 (4-chloro-3-hydroxyanthranilic acid), an inhibitor of 
QUIN synthesis (IC50 = 32 µM [135-137]), which may further broaden the possibility for 
neuroprotection. Compound 28 successfully improved functional recovery and preserved 
white matter after spinal cord injury in adult Hartley guinea pigs [138]. 4,5-, 4,6-Disubstituted 
and 4,5,6-trisubstituted 3-OH-ANA derivatives were also synthesized and demonstrated to 
have inhibitory action on 3-HAO [139]. The positioning of electron withdrawing groups in the 
4- and 5-positions increased the potency of enzyme inhibition. NCR-631 is also a 3-
hydroxyanthranilate analog (structure is not available) which exerted protective effects 
against anoxia and neuroinflammation-related damage [140]and demonstrated anticonvulsant 
effects, as well [141]. 2-Aminonicotinic acid 1-oxides, e.g. 29 (6-methyl-2-aminonicotinic 
acid 1-oxide; IC50 = 1.1 µM), represent another promising group with inhibitory activity on 3-
HAO [142]. Although the inhibitors of both kynureninase and 3-HAO would yield interesting 
compounds for future drug development, they are currently not in the pipeline with regard to 
the modulation of TRP metabolism inneurotherapeutic aspect. 
 
3. Kynurenine pathway inhibitors: advances in the recent patent literature 
(2012-2015) 
 
Thomson Innovation Patent Export was utilized to search for patents with the 
demonstrationlineation of inhibitors of the kynurenine pathway as neurotherapeutics applying 
the assessment period of 2012-2015. Twenty patents have been were found, out of which 
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19 
EP2664615 [143]was excluded because the invention related to novel compounds for the 
inhibition of glycogen synthase kinase-3β and/or modulation of NMDA channel activity, not 
for the inhibition of enzymes of the kynurenine pathway. There were several overlaps 
amongst the remaining 19 patents, due to the publication of the same inventions under the 
egis of World Intellectual Property Organization, United States Patent and Trademark Office 
and European Patent Office. Therefore, finally, 11 inventions could be identified out of which 
one deals with the inhibitors of IDO1, 2 and TDO, and the remaining deal with the inhibitors 
of KMO. 
 
3.1 Indolamine 2,3-dioxygenase 1 and 2, tryptophan 2,3-dioxygenase 
3.1.1 2,3-diamino-furo[2,3-c]pyridine and 2,3-diamino-benzo[b]thiophene derivatives 
The patent document WO2014186035 [144](EP2970173) reports the synthesis and 
experimental data on 2,3-diamino-furo[2,3-c]pyridine and 2,3-diamino-benzo[b]thiophene 
derivatives as inhibitors of IDO1,2 and TDO (Fig. 7.). The IC50 values were determined 
applying human in vitro IDO1, IDO2 and TDO biochemical and cellular enzyme assays. The 
lead compounds of the two derivative groups are 30 (N
3
-(3-chloro-4-fluorophenyl)furo[2,3-
c]pyridine-2,3-diamine; IC50 values are < 200 nM for IDO1, < 1000 nM for IDO2 and 500-
2000 nM for TDO) and 31 (N
3
-(3-chloro-4-fluorophenyl)benzo[b]thiophene-2,3-diamine; 
IC50 values are < 200 nM for IDO1 and < 500 nM for TDO). With regard to SAR, the 
modifications of substitutions on the phenyl ring would have significant impact on inhibitory 
potency. Although the application of different substituents on at different positions have 
diverse effect on the inhibition of IDO1 and TDO, it can be highlighted that when the 
halogenation was applied in both the C-2 and C-4 positions (e.g. 32; N
3
-(2-chloro-4-
fluorophenyl)furo[2,3-c]pyridine-2,3-diamine) or trisubstitution with halogens was performed 
(e.g. 33; N
3
-(3,5-dichloro-4-fluorophenyl)furo[2,3-c]pyridine-2,3-diamine) the inhibitory 
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20 
potency on IDO1 became considerably decreased without affecting the inhibitory potency on 
TDO (IC50 values are > 1000 nM for IDO1, 500-2000 nM for TDO and > 1000 nM for IDO1, 
500-2000 nM for TDO, respectively). On the other hand, the lack of substitution (34; N
3
-
phenylfuro[2,3-c]pyridine-2,3-diamine) resulted in a slight decrease ion IDO1 inhibition (IC50 
= 200-1000 nM) and a slight increase ion TDO inhibition (IC50< 500 nM). With regard to the 
application of substituents onat the furo[2,3-c]pyridine moiety, it can be concluded that the 
application of substituents inatthe C-7 position (e.g. 35; N
3
-(3-chloro-4-fluorophenyl)-7-
(pyridine-4-yl)furo[2,3-c]pyridine-2,3-diamine; IC50< 200 nM for IDO1 and < 500 nM for 
TDO; 36; N
3
-(3,4-difluorophenyl)-7-(pyridine-4-yl)furo[2,3-c]pyridine-2,3-diamine; IC50< 
200 nM for IDO1, < 1000 nM for IDO2 and < 500 nM for TDO; 37; 7-chloro-N
3
-(3-chloro-4-
fluorophenyl)furo[2,3-c]pyridine-2,3-diamine; IC50< 200 nM for IDO1 and < 500 nM for 
TDO) didoes not considerably influence the activity of the molecule on IDO1 and IDO2, but 
may alter the activity of molecule on TDO depending on the applied substituents (e.g. 38; N
3
-
(3-chloro-4-fluorophenyl)-7-propylfuro[2,3-c]pyridine-2,3-diamine; IC50< 200 nM for IDO1 
and > 2000 nM for TDO). The amidation of amine moiety either inatthe C-2 position (e.g. 39; 
ethyl(3-((3-chloro-4-fluorophenyl)amino)furo[2,3-c]pyridin-2-yl)carbamic acid) or at both 
positions (e.g. 40; methyl-N-(3-chloro-4-fluoro-phenyl)-N-[2-
(methoxycarbonylamino)furo[2,3-c]pyridin-3-yl]carbamate) led to thea decrease ofin 
inhibitory activity (IC50 values are > 1000 nM for IDO1 and > 2000 nM for TDO in both 
cases). The SAR in 2,3-diamino-benzo[b]thiophene derivatives is quite similar to that of 2,3-
diamino-furo[2,3-c]pyridine derivatives. The in vivo effects of some of the above-mentioned 
compounds have been tested in different preclinical models. Amongst others, the drugs 30,31, 
35, 36 and 37 were applied orally following intraperitoneal lipopolysaccharide injection into 
mice to model immune activation and to study IDO1 expression and activity. Plasma KYN 
levels have been were measured as the biochemical indicator of decreased IDO activity. The 
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21 
use of compounds 30, 35, 36 and 37 resulted in more than 50% a reduction more than 50% in 
KYN level, whileereas31 resulted in a reduction of between 25-50%. Compounds 30, 35, 36 
and 37 significantly decreased tumor growth following oral administration when CT-26 
mouse colorectal tumor forming cells were injected subcutaneously in the right flank of 
Balb/c mice. With regard to the effect on KYN levels in plasma and tumor tissue, 30 induced 
a81% and a 62% decrease, respectively, whileereas35 induced a 81% and a 67% decrease, 
respectively. Compounds 30 and 35were proved capable of penetrating acrossthe BBB 
following intravenous injection, indicating that these compounds can be useful for IDO or 
TDO-associated brain diseases as well. 
 
3.2 Kynurenine 3-monooxygenase 
 
3.2.1 Aryl pyrimidines 
As mentioned above, aryl pyrimidines would be promising candidates of KMO inhibition 
(Fig. 8.)[113]. The patent documents US20130029988[145](WO2011091153, EP252844), 
US20130331370[146](WO2010017179, EP2331095), 
WO2013016488[147](US20140329816, EP2736337), 
WO2013033068[148](US20140329795, EP2751086), and WO2013033085[149](EP2750677) 
also deal with inventions in the field of aryl pyrimidines as KMO inhibitors. The aryl 
pyrimidine skeleton was proposed on the basis that the pyrimidine N-3 nitrogen would mimic 
the carbonyl oxygen of L-KYN and some of its analogues (17, 19), whileereas the N-1 
nitrogen would mimic the amino group of the above-mentioned compounds [119]. The above-
mentioned patent documents and the comprehensive work of Toledo-Sherman et al. 
[119]delineate the effects of modifications of the aryl ring at the C-4 position, the effects of 
substituents at the pyrimidine core,and the effects of carboxylic acid modifications (mainly 
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22 
via esterification or amidation), the application of acid bioisosteres and the non-acidic 
replacement at the C-6 position on inhibitory potency of the molecule. The inhibitory potency 
was tested via the application of biochemical assays using mitochondrial fractions derived 
from mice, rats and human liver tissues and via the application of cellular assays using CHO 
cell lines expressing human or rodent KMO enzymes and the physiologically more relevant 
primary cells with endogenous levels of KMO. The level of inhibition was expressed either as 
the percentage of inhibition at 10 µM concentration of the tested compounds or as IC50 
values. With regard to the modifications of the aryl ring at the C-4 position, 41 (4-(3,4-
dichlorophenyl)-pyrimidine-6-carboxylic acid; 105.5%, IC50 = 0.6 nM) and 42 (4-(3-
chlorophenyl)-pyrimidine-6-carboxylic acid; 105.6%, IC50 = 0.5 nM) would serve as lead 
compounds with excellent inhibitory potency. The removal of chlorines (43; 4-phenyl-
pyrimidine-6-carboxylic acid; IC50 = 38 nM), the saturation of the phenyl ring (44; 4-
cyclohexyl-pyrimidine-6-carboxylic acid; IC50 = 340 nM) the replacement of the phenyl ring 
with a heteroaryl ring (e.g. 45; 4-pyridine-3-yl-pyrimidine-6-carboxylic acid; IC50 = 990 nM) 
and the introduction of large substituents (e.g. 46; 4-biphenyl-3-yl-pyrimidine-6-carboxylic 
acid; 70%, IC50 = 2.13 µM) similarly resulted in substantial decrease in inhibitory potency. 
The application of methyl group in at the C-2 position in 41or 47 (2-[6-(3,4-
dichlorophenyl)pyrimidin-4-yl]-4-methyl-oxazole; 100.65%) considerably reduced the 
potency of inhibition (48; 4-(3,4-dichlorophenyl)-2-methyl-pyrimidine-6-carboxylic acid; 
IC50 = 12 nM; 49;2-[6-(3,4-dichlorophenyl)-2-methyl-pyrimidin-4-yl]-4-methyl-oxazole; 
46.84%) which would can be attributed to steric properties interfering with the hydrogen 
bonding interaction of KMO with the N-1 nitrogen. The application of a methyl group in at 
the C-5 position in 41also considerably decreased the potency of inhibition (50; 4-(3,4-
dichlorophenyl)-5-methyl-pyrimidine-6-carboxylic acid; IC50 = 10 nM), probably due to 
disturbing the co-planarity of the biaryl ring system via posing substantial strain on ring 
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23 
torsions. Although the penetrationacrossof the BBB is not obligatory in case of KMO 
inhibitors, it would broaden the mechanism of action by local CNS effects. The presence of 
carboxylic acid moiety would be is critical to form an ionic salt bridge with a guanidinium 
moiety of an arginine of KMO;,but however it considerably decreases the penetration 
acrossthrough the BBB. It seems that esterification (e.g. 51; isopropyl-6-(3,4-
dichlorophenyl)pyrimidine-4-carboxylate; 100%) or amidation (e.g. 52; 6-(3,4-
dichlorophenyl)-N-methyl-pyrimidine-4-carboxamide; 100.31%) retains the inhibitory 
potential of the majority of molecules,;buthowever it depends on the side-chain with some 
exceptions (e.g. 53; N-(2-amino-1-methyl-2-oxo-ethyl)-6-(3,4-dichlorophenyl)pyrimidine-4-
carboxamide; 47.73%). With regard to the application of acid bio-isosteres, such as 1H-
tetrazole (54; 4-(3,4-dichlorophenyl)-6-(1H-tetrazol-5-yl)pyrimidine; 102.87%, IC50 = 2 nM), 
oxadiazolone (55; 3-[4-(3,4-dichlorophenyl)pyrimidin-6-yl]-4H-1,2,4-oxadiazol-5-one; 
101.78%, IC50 = 12 nM) or acidic acyl sulfonamide (e.g. 56; N-[4-(3,4-
dichlorophenyl)pyrimidine-6-carbonyl]-benzenesulfonamide; 100.73%, IC50 = 25 nM) at the 
C-6 position in 3,4-dichlorophenyl-substituted molecules at the C-4 position resulted in 
retained inhibition of KMO. However, non-acidic replacement, with moieties such as 
carbonitrile (57; 4-(3,4-dichlorophenyl)pyrimidine-6-carbonitrile; 68.36%, IC50 = 4 µM), 
1,2,4-oxadiazole (58; 4-(3,4-dichlorophenyl)-6-(1,2,4-oxadizol-3-yl)pyrimidine; 68.52%, IC50 
= 5.06 µM), thiazole (59; 4-(3,4-dichlorophenyl)-6-thiazol-2-yl)pyrimidine; 48%),and or 1H-
pyrazole (60; 4-(3,4-dichlorophenyl)-6-(1H-pyrazol-3-yl)pyrimidine; 19%) provided 
decreased potency of inhibition. As substitution of the pyrimidine moiety at the C-6 position 
is restricted, further optimization of BBB penetration with retained KMO inhibition has been 
proposed via the substitutions ion the phenyl ring. Accordingly, 61 (4-(3-chloro-4-
cyclopropoxy-phenyl)-pyrimidine-6-carboxylic acid; 100%, IC50 = 0.5 nM) could be detected 
in brain tissues following intravenous or per os administration as well, and exerted profound 
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24 
elevation in extracellular KYN, anthranilic acidAA and KYNA levels. 
 
3.2.2 Pyrimidine benzenesulfonamides 
In addition to the delineation of pyrimidine carboxylic acids, in the patent 
documentWO2013033085 [149](EP2750677), the patent document also reports the percentage 
of inhibition at 10 µM of some 4-(3-chloro-4-cyclopropoxyphenyl)-substituted pyrimidine 
benzenesulfonamides (Fig. 9.). Although the application of the pyrimidine 
benzenesulfonamide moiety itself did not result in notable KMO inhibition (62; N-[4-(3-
chloro-4-cyclopropoxyphenyl)pyrimidine-6-yl]-benzenesulfonamide; 73%), the fluorination 
of the phenyl ring either in para (63; N-[4-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-6-yl]-
4-fluorobenzene-1-sulfonamide; 98%) or in ortho position (64; N-[4-(3-chloro-4-
cyclopropoxyphenyl)pyrimidine-6-yl]-2-fluorobenzene-1-sulfonamide; 96%) could 
considerably increase the potency of inhibition. 
 
3.2.3 Phenylthiazolebenzenesulfonamides 
US8710237[150](priority publications: WO2008022281, US20120022052, EP2054397) 
reports experimental data on phenylthiazolebenzenesulfonamides (Fig. 10.), including 20 and 
21. Although the validity of results demonstrating the beneficial effects of 21 has been 
criticized in light of pharmacokinetic studies that 21 is neither a prodrug for 20 nor a potent 
KMO inhibitor [118], the invention reports several other compounds with promising 
inhibitory effects. The percentage of inhibition at 10 µM concentration of the tested 
compounds applying rat liver homogenates has been investigated in some molecules. With 
regard to SAR, the effects of substitution at the nitrogen of sulfonamide moiety and at the C-5 
position of thiazole moiety were assessed. The application of ethylcarboxylate group (65; 3,4-
dimethoxy-N-[4-(3-nitrophenyl)thiazole-2-yl]-N-(ethylcarboxylate)benzenesulfonamide) 
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25 
resulted in higher inhibitory potency (84%) compared to that of a simple methyl group (66; 
3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazole-2-yl]-N-(methyl)benzenesulfonamide; 52%). 
Compound 65 significantly increased the brain concentrations of KYN and significantly 
decreased that of 3-OH-KYN in a dose-dependent manner 5 h following intraperitoneal 
administration, whereasile66 only decreased 3-OH-KYN concentrations. Nevertheless these 
drugs did not affect the levels of either brain KYNA and QUIN, or plasma KYN, KYNA, 3-
OH-KYN and QUIN levels. The application of a six-membered N-containing ring (67; 3,4-
dimethoxy-N-[4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)-1,3-thiazol-2-
yl]benzenesulfonamide), especially that of comprising oxygen atin para position (68; 3,4-
dimethoxy-N-[4-(3-nitrophenyl)-5-morpholinomethyl-1,3-thiazol-2-yl]benzenesulfonamide) 
resulted in higher inhibitory potency (24% and 64%, respectively) compared to that of a five-
membered N-containing ring (69; 3,4-dimethoxy-N-[4-(3-nitrophenyl)-5-(pyrrolidin-1-
ylmethyl)-1,3-thiazole-2-yl]benzenesulfonamide; 9%). Compound 67 significantly decreased 
the brain concentrations of 3-OH-KYN and QUIN levels in a dose-dependent manner 5 h 
following intraperitoneal administration, while Compound 68 and 69 only decreased 3-OH-
KYN concentrations. Nevertheless these drugs did not affect the levels of either brain or 
plasma KYN and KYNA. In light of its inhibitory potency, the above-mentioned effect of 69 
is surprising and it would be attributed to prodrug properties. 
 
3.2.4 Phenylthiadiazolebenzenesulfonamides 
The patent document US20120046324[151](EP2420494, WO2008022286) reports some 
scientific data about on the assessment of phenylthiadiazolebenzenesulfonamides (Fig. 11.). 
In light of the percentage of inhibition at 10 µM, it can be concluded that the application of 
1,2,4-thiadiazole moiety (e.g. 70; 3,4-dimethoxy-N-[3-(phenyl)-1,2,4-thiadiazol-5-
yl]benzenesulfonamide; 73.61%) resulted in higher inhibitory potency compared to the 1,3,4-
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26 
thiadiazole moiety (e.g. 71; 3,4-dimethoxy-N-[5-(phenyl)-1,3,4-thiadiazol-2-
yl]benzenesulfonamide; 60.03%). 
 
3.2.5trans-2-Substituted-cyclopropane-1-carboxylic acids 
The further development of trans-2-substituted-cyclopropane-1-carboxylic acids is based on 
the promising preclinical data obtained from the experiments with 19. The patent documents 
WO2013151707[152](EP2833879, US20150057238) and WO2015047978[153]report 
molecules ofdeveloped either as a result of modification of the benzoyl ring or further 
substitution of the cyclopropane moiety, or the modification of carboxylic acid moiety via 
amidation or application of acid bioisosteres (Fig. 12.). In light of the percentage of inhibition 
at 30 µM, it can be concluded that modification of the benzoyl ring did not considerably 
influence the inhibitory potential (e.g. 72; (1S,2S)-2-(7-chloro-2,3-dihydro-1-benzofuran-5-
carbonyl)cyclopropane-1-carboxylic acid; 100.3%). The methyl-substitution of cyclopropane 
moiety was assessed, as well. The application of a methyl group in at the C-1 position did not 
considerably affect the inhibitory potency (73; (1S,2S)-2-(3,4-dichlorobenzoyl)-1-
methylcyclopropane-1-carboxylic acid; 98.6%).However, when this methyl group was 
introducedinatthe C-3 position, its effects depended on steric conditions (74; (1S,2S,3S)-2-
(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-carboxylic acid; 52.5%; 75 (enantiomer of 
74); (1R,2R,3R)-2-(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-carboxylic acid; 100.6%; 
76 (C-3 epimer of 74); (1S,2S,3R)-2-(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-
carboxylic acid; 96.7%). However, the disubstitution of methyl groups inat the same position 
considerably decreased the inhibitory potency (77; (1R,3R)-3-(3,4-dichlorobenzoyl)-2,2-
dimethylcyclopropanecarboxylic acid; 54%; 78 (enantiomer of 77); (1S,3S)-3-(3,4-
dichlorobenzoyl)-2,2-dimethylcyclopropanecarboxylic acid; 15.4%). With regard to tThe 
application of acid bioisosteres, such as 1H-tetrazole (79; (3,4-dichlorophenyl)-[(1S,2S)-2-
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27 
(1H-tetrazol-5-yl)cyclopropyl]methanone; 101%) or oxadiazolone (80; 3-[(1S,2S)-2-(3,4-
dichlorobenzoyl)cyclopropyl]-4H-1,2,4-oxadiazol-5-one; 101%), resulted in retained 
inhibition of KMO. However, amidation of carboxylic acid moiety considerably decreased the 
potency of inhibition (81; (1S,2S)-2-[(3-chloro-4-
cyclopropoxyphenyl)carbonyl]cyclopropane-1-carboxamide; 42%). 
 
3.2.6 Isoxazoles and isoxazolines 
The patent document US20120329812[154](WO2010017132A1) delineates several 3,4- or 
3,5-disubstituted isoxazoles and isoxazolines as KMO inhibitors (Fig. 13.). With regard to 
SAR, the effects of the partial saturation of the isoxazole moiety and the effect ofor the 
application of substituents at the C-4 or C-5 position in molecules substituted with the 3,4-
dichlorophenyl-substituted molecules moiety at the C-3 position could bewere assessed via 
the percentage of inhibition at 10 µM. The application of carboxylic moiety itself either at the 
C-4 (82; [3-(3,4-dichlorophenyl)-isoxazol-4-yl]-acetic acid; 74.7%) or at the C-5 position (83; 
[3-(3,4-dichlorophenyl)-isoxazol-5-yl]-acetic acid; 74.53%) alikewise resulted in reduced 
potency of inhibition. However, the partial saturation of the isoxazole moiety in the former 
molecule considerably increased the inhibitory potency (84; [3-(3,4-dichlorophenyl)-4,5-
dihydro-isoxazol-4-yl]-acetic acid; 101.21%). Although esterification did not influence the 
activity (e.g. 85; [3-(3,4-dichlorophenyl)-4,5-dihydro-isoxazol-4-yl]-acetic acid methyl ester; 
102.45%), amidation (e.g. 86; 2-[3-(3,4-dichlorophenyl)-4,5-dihydro-isoxazol-4-yl]-
acetamide; 60.4%) or the introduction of a methyl group at the C-5 position (e.g. 87; [3-(3,4-
dichlorophenyl)-5-methyl-4,5-dihydro-isoxazol-4-yl]-acetic acid; 84.5%) alikeboth 
considerably decreased KMO inhibition. These results would be attributed to steric effects. 
 
4. Conclusions 
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28 
Certain enzymes of the KYN pathway of TRP metabolism, especially those having a central 
initiating role in the pathway (such as IDO and TDO) or that are responsible for the formation 
of neuroactive kynurenines (such as KATs, KMO, kynureninase, and 3-HAO) serve as 
interesting targets for pharmaceutical drug design, in light of the involvement of the 
alterations of the pathway in numerous disorders, including neurological conditions. There 
has been a considerable development in this field in recent decades with emerging preclinical 
data supporting the beneficial effects of these compounds. Although there is a constant need 
for further development of lead compounds to achieve drugs with appropriate effect/side-
effect profile, some of the available substances are already worth testing in clinical trials. 
 
5. Expert opinion 
In recent years, numerous research has been done to explore the involvement of TRP 
metabolism in neurological and psychiatric disorders. Although clinical and preclinical data 
are reassuring and yield several possibilities for therapeutic intervention, there is a paucity of 
applicable drugs in daily clinical practice. With regard to KYNA derivativesanalogs, most of 
them, such as GV150526 in stroke [155], were unable to exert significant improvement in 
clinical outcome. However, there are some other promising candidates, including halogenated 
compounds and KYNA amides, which could be utilized in future clinical studies 
[4,67,156,157]. 4-Cl-KYN (also known as AV-101), the BBB-penetrable prodrug of 7-Cl-
KYNA,a moleculewhichdemonstratinges enhanced antagonism at glycine/NMDA receptors, 
was successfully assessed in a Phase I trial (ClinicalTrials.gov identifier: NCT01483846) and 
an investigational new drug application for neuropathic pain has been filed with the United 
States Food and Drug Administration. Furthermore, there is anongoing recruiting periodment 
for a trial the assessingmentthe therapeutic potential of this drug in major depressive disorder 
(ClinicalTrials.gov identifier: NCT02484456). With regard to the metabolic shift concept 
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29 
with the aim of restoration ofversing pathological alterations at the level of neuroactive 
compounds of the KYN pathway of TRP metabolism, several enzyme inhibitors have been 
developed. The determination of enzyme structures considerably promoted the development 
of potent inhibitors,; most of them were designed as a structural analog of the natural enzyme 
substrate. As IDO/TDO activation would serve as a double-edged sword in the CNS, i.e. 
protective immunosuppressive response vs. considerable elevation in the levels of cytotoxic 
TRP metabolites, the manipulation of these enzymes should be implemented very cautiously. 
Nevertheless,1 and 2 seems to be beneficial in preclinical studies on their antitumor effect. 
The enrollment of patients in a Phase I/II study assessing the efficacy of 1 in combination 
with temozolomidein primary malignant brain tumors is ongoing (ClinicalTrials.gov 
identifier: NCT02052648). In light of recent preclinical data with 2,3-diamino-furo[2,3-
c]pyridine and 2,3-diamino-benzo[b]thiophene derivatives, these compounds deserve 
attention for future clinical studies as well. Although most neurological disorders can be 
characterized by the relative deficiency of the neuroprotectantKYNA, the excessive elevation 
of this compound would may result in deteriorated cognitive functions. Therefore, the 
application of KAT inhibitors in these conditions, such as schizophrenia, would have 
rationalejustification. Although 13, 14 and 15 all have promising preclinical properties, there 
are noclinical studies ongoing with KAT inhibitors. Probably the hottest topic in the field of 
inhibitors of KYN pathway as neurotherapeutics is the development of KMO inhibitors with 
the aim of reducing the levels of toxic compounds and shifting the pathway toward the 
production of neuroprotective KYNA to restore the balance of altered metabolite levels. 
Although 19 and substances achieved from the further development of trans-2-substituted-
cyclopropane-1-carboxylic acids provided reassuring preclinical data, there are currently no 
clinical trials ongoing with any of these compounds. Furthermore, the situation is the same 
with the more potent phenylthiazolebenzenesulfonamides, including 20, 
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30 
phenylthiadiazolebenzenesulfonamides, isoxazolesand isoxazolines. The advanced 
development of aryl pyrimidines and pyrimidine benzenesulfonamides based on well-
designed SAR studies in recent years holds the promise of the achievement development of 
potent and selective compounds. Hopefully, some of these molecules would be appropriate 
for future clinical testing if sufficient reassuring preclinical data were gathered. Although 
promising kynureninase and 3-HAO inhibitors also exist, currently the design of KMO 
inhibitors seems to be the pipeline of drug development with the aim of the reduction of the 
levels of neurotoxic compounds of the KYN pathway. With regard to future research in this 
field, in addition to the development of drugs with much higher selectivity, enhanced potency 
and better side-effect profile, a special attention should also be paid to the better 
characterization of neurochemical alterations and the exploration of possible genetic 
background as well to enablethe establishment ofsetting up the best individualized therapy. 
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Figure captions 
 
Figure 1. The schematic depiction of the kynurenine pathway of tryptophan metabolism. 
 
Figure 2.Reference inhibitors of indolamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase 
reported in the literature. 
 
Figure 3.Reference inhibitors of kynurenine aminotransferase reported in the literature. 
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49 
Figure 4.Reference inhibitors of kynurenine 3-monooxygenase reported in the literature. 
 
Figure 5.Reference inhibitors of kynureninase reported in the literature. It should be noted 
that 16and 17in Fig. 4. can also exert inhibitory effect on kynureninase. 
 
Figure 6.Reference inhibitors of 3-hydroxyanthranilate 3,4-dioxygenase reported in the 
literature. 
 
Figure 7. Some 2,3-diamino-furo[2,3-c]pyridine and 2,3-diamino-benzo[b]thiophene 
derivatives as inhibitors of indolamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. 
 
Figure 8. Certain aryl pyrimidines as inhibitors of kynurenine 3-monooxygenase. 
 
Figure 9. Some pyrimidine benzenesulfonamides as inhibitors of kynurenine 3-
monooxygenase. 
 
Figure 10. Some phenylthiazolebenzenesulfonamides as inhibitors of kynurenine 3-
monooxygenase. It should be noted that 20 and 21 in Fig. 4. also belong to this chemical 
group. 
 
Figure 11. Two examples of phenylthiadiazolebenzenesulfonamides as inhibitors of 
kynurenine 3-monooxygenase. 
 
Figure 12. Certain trans-2-substituted-cyclopropane-1-carboxylic acids as inhibitors of 
kynurenine 3-monooxygenase. It should be noted that 19 in Fig. 4. also belongs to this 
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chemical group. 
 
Figure 13. Some isoxazoles (82 and 83) and isoxazolines(84-87) as inhibitors of kynurenine 
3-monooxygenase. 
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